Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...

In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

John Egan is a veteran personal finance writer whose work has been published by outlets such as Bankrate, Experian, Newsweek Vault and Investopedia. Michelle is a lead editor at Forbes Advisor. She ...

The Ravens never quit and never found consistency. The focus will quickly turn to offseason decisions. Even shorthanded, the Steelers knew they could move the ball against Baltimore's defense. Fumbles ...

A breakdown cover policy provides peace of mind that help is just a phone call (or tap on your phone’s app) away, when your car fails you. But what are the best breakdown deals out there? We’ve looked ...

Ever since 2007, Netflix has been one of the biggest players in the world of streaming, offering high-quality shows and movies like Stranger Things, Squid Game, Black Mirror, and so many more. The ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...